SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation D614G


Basic Characteristics of Mutations
Mutation Site D614G
Mutation Site Sentence Two doses of 100 mug of mRNA-1273 induced reciprocal ID50 mean neutralizing antibody titers against live SARS-CoV-2 D614G and B.1.351 of 3,300 and 240,respectively.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype -
Viral Reference NC_045512
Functional Impact and Mechanisms
Disease Cell line    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 34417590
Title mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Author Corbett KS,Werner AP,Connell SO,Gagne M,Lai L,Moliva JI,Flynn B,Choi A,Koch M,Foulds KE,Andrew SF,Flebbe DR,Lamb E,Nurmukhambetova ST,Provost SJ,Bock KW,Minai M,Nagata BM,Ry AV,Flinchbaugh Z,Johnston TS,Mokhtari EB,Mudvari P,Henry AR,Laboune F,Chang B,Porto M,Wear J,Alvarado GS,Boyoglu-Barnum S,Todd JM,Bart B,Cook A,Dodson A,Pessaint L,Steingrebe K,Elbashir S,Sriparna M,Pekosz A,Andersen H,Wu K,Edwards DK,Kar S,Lewis MG,Boritz E,Moore IN,Carfi A,Suthar MS,McDermott A,Roederer M,Nason MC,Sullivan NJ,Douek DC,Graham BS,Seder RA
Journal Nature immunology
Journal Info 2021 Oct;22(10):1306-1315
Abstract B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 microg of Moderna's mRNA-1273 vaccine, a single immunization of 30 microg, or no vaccine. Two doses of 100 microg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log(10) reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log(10) reduction in nasal swabs in the 100-microg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.